Covered recipient · General Payments record
ALEJANDRA TORO BEJARANO
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2021–2024
$622.66
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $314.81 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $54.48 | 3 |
| Exeltis, USA Inc. | $49.50 | 3 |
| PFIZER INC. | $38.83 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $32.25 | 1 |
| Hologic Sales and Service, LLC | $32.09 | 1 |
| Astellas Pharma US Inc | $24.99 | 1 |
| Amgen Inc. | $19.13 | 1 |
| ABBVIE INC. | $17.92 | 1 |
| SHIELD THERAPEUTICS INC | $15.67 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.60 | 1 |
| Organon LLC | $14.35 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.92 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233176 | CMS |
| Amgen Inc. | $19.13 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726275 | CMS |
| Astellas Pharma US Inc | $24.99 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139302950 | CMS |
| Biogen, Inc. | $17.68 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104874294 | CMS |
| Biogen, Inc. | $20.58 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104855974 | CMS |
| Biogen, Inc. | $16.22 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104857108 | CMS |
| Exeltis, USA Inc. | $17.56 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150006220 | CMS |
| Exeltis, USA Inc. | $13.80 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150006222 | CMS |
| Exeltis, USA Inc. | $18.14 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150006224 | CMS |
| Hologic Sales and Service, LLC | $32.09 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1084867801 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $32.25 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154684789 | CMS |
| Organon Llc | $14.35 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136300696 | CMS |
| PFIZER INC. | $21.30 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131636108 | CMS |
| PFIZER INC. | $17.53 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130881050 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.60 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153510297 | CMS |
| SHIELD THERAPEUTICS INC | $15.67 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150156239 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.